Literature DB >> 3237218

Drugs as allergens: detection and combining site specificities of IgE antibodies to sulfamethoxazole.

D G Harle1, B A Baldo, J V Wells.   

Abstract

An immunoassay was developed for the detection of sulfamethoxazole reactive IgE antibodies in the sera of patients who experienced life threatening anaphylactic reactions following the ingestion of co-trimoxazole (trimethoprim and sulfamethoxazole). Patients who had significant levels of sulfamethoxazole reactive IgE antibodies in their sera did not have IgE antibodies that reacted with trimethoprim-Sepharose. Inhibition experiments with a number of sulfonamides to determine the fine structural specificities of the sulfamethoxazole reactive IgE antibodies in three patients revealed that sulfamethoxazole and, depending on the serum, sulfamerazine and sulfamethizole, were the most potent inhibitors of IgE binding, whereas the parent sulfonamide, sulfanilamide, was a very poor inhibitor. From a detailed examination of structure-activity relationships, we concluded that the 5-methyl-3-isoxazolyl group on the sulfamethoxazole molecule was the allergenic determinant for all three patients with the 5-methyl group being particularly important for IgE antibody recognition. The assays for the detection of IgE antibodies to sulfamethoxazole and trimethoprim should prove useful for the diagnosis of immediate hypersensitivity to co-trimoxazole and perhaps for monitoring drug therapy in AIDS patients where a high incidence of adverse reactions to co-trimoxazole has been reported.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3237218     DOI: 10.1016/0161-5890(88)90050-8

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  15 in total

Review 1.  Recognising antibacterial hypersensitivity in children.

Authors:  A Romano
Journal:  Paediatr Drugs       Date:  2000 Mar-Apr       Impact factor: 3.022

2.  Use of acetazolamide in sulfonamide-allergic patients with neurologic channelopathies.

Authors:  Daniel Platt; Robert C Griggs
Journal:  Arch Neurol       Date:  2011-12-12

3.  Safety of celecoxib in individuals allergic to sulfonamide: a pilot study.

Authors:  Lori E Shapiro; Sandra R Knowles; Elizabeth Weber; Manuela G Neuman; Neil H Shear
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

4.  Allergic manifestations of human immunodeficiency virus (HIV) infection.

Authors:  A Carr; D A Cooper; R Penny
Journal:  J Clin Immunol       Date:  1991-03       Impact factor: 8.317

Review 5.  Hypersensitivity reactions to non-beta-lactam antibiotics.

Authors:  Stephen A Tilles; Christopher G Slatore
Journal:  Clin Rev Allergy Immunol       Date:  2003-06       Impact factor: 8.667

6.  Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity.

Authors:  James C Sacco; Mahmoud Abouraya; Alison Motsinger-Reif; Steven H Yale; Catherine A McCarty; Lauren A Trepanier
Journal:  Pharmacogenet Genomics       Date:  2012-10       Impact factor: 2.089

Review 7.  Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy.

Authors:  S Knowles; L Shapiro; N H Shear
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

Review 8.  Allergic adverse reactions to sulfonamides.

Authors:  Geneviève Choquet-Kastylevsky; Thierry Vial; Jacques Descotes
Journal:  Curr Allergy Asthma Rep       Date:  2002-01       Impact factor: 4.919

Review 9.  Sulfonamide Hypersensitivity.

Authors:  Timothy G Chow; David A Khan
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-01       Impact factor: 8.667

Review 10.  Sulfonamide allergy and cross-reactivity.

Authors:  Carolyn C Brackett
Journal:  Curr Allergy Asthma Rep       Date:  2007-04       Impact factor: 4.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.